Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Screening laboratory values within 30 days prior to administration of the study drug: WBC ≥ 1200/μL; ANC ≥ 1000/μL; Platelets ≥ 75,000/μL; Hemoglobin ≥ 9.0 g/dL; Creatinine ≤ 1.5 mg/dL; AST/ALT ≤ 3 x ULN for patients with no liver metastases; AST/ALT ≤ 5 x ULN for patients with liver metastases; Bilirubin ≤ 1.5 mg/dL except for participants with Gilbert's disease. Unremarkable ECGs, with PR intervals of less than 200 msec and QTcF intervals (corrected with Frederica's method) of less than 450 msec.